A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%
ClinicalTrials.gov ID
NCT02173249
Lead Sponsor
Aciex Therapeutics, Inc.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
11Actual
Last Update Posted
Sep 14, 2017Actual
Start Date
Jun 2014
Primary Completion Date
Aug 2014Actual
Completion Date
Aug 2014Actual
Brief Summary
The purpose of this study is to evaluate the Plasma Pharmacokinetics and Safety of AC 170 0.24% in Healthy, Adult Subjects when used twice daily for one week.
Healthy
AC 170 0.24%
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
at least 18 and no older than 55 years of age
be able to self-administer eye drops or have a parent/legal guardian available for this purpose
have blood and urine analysis within normal limits
have ocular health within normal limits
Exclusion Criteria:
known contraindications or sensitivities to the study medication or its components
have any active systemic or ocular disorder (other than refractive disorder)
have inability to comply with controlled diet
have used prescription or non prescription drugs within washout period and throughout study
have used alcohol or tobacco within the washout period